摘要
目的探讨芪苈强心胶囊联合依那普利治疗充血性心力衰竭的临床疗效。方法选取医院2016年5月至2018年4月收治的患者93例,按随机数字表法分为对照组(46例)和治疗组(47例)。两组患者均接受常规抗心力衰竭治疗,并口服依那普利;治疗组患者加服芪苈强心胶囊,均连续治疗2个月。结果治疗组总有效率为89.36%,显著高于对照组的78.26%(P<0.05);治疗后,两组患者的左心室射血分数(LVEF)、心输出量(CO)明显升高,左心室收缩末期容积(LVESV)、血清氨基末端脑钠肽前体(NT-proBNP)水平明显降低(P<0.05),6min步行距离显著增加(P<0.05),且治疗组患者上述指标改善程度明显优于对照组(P<0.05);治疗期间,两组患者均无明显不良反应发生。结论芪苈强心胶囊联合依那普利治疗充血性心力衰竭能改善心功能并降低NT-proBNP水平,且安全性较好。
Objective To investigate the clinical efficacy of Qili Qiangxin Capsules combined with enalapril in the treatment of congestive heart failure. Methods Totally 93 patients with congestive heart failure admitted to our hospital from May 2016 to April 2018 were selected and divided into the control group( n = 46) and the treatment group( n = 47) according to the random number table method. The patients in the two groups received routine anti-heart failure treatment and enalapril,on this basis,the patients in the treatment group were given Qili Qiangxin Capsules. All patients were treated continuously for 2 months. Results The total effective rate of the treatment group was 89. 36%,which was significantly higher than 78. 26% of the control group( P < 0. 05). After treatment,the left ventricular ejection fraction( LVEF) and cardiac output( CO) were significantly increased,the levels of left ventricular end-systolic volume( LVESV) and N-terminal pro-brain natriuretic peptide( NT-proBNT) were significantly decreased( P < 0. 05),and 6-minute walk test( 6 MWT) was significantly increased in the two groups( P < 0. 05),and the improvement of the above indexes in the treatment group was significantly better than that in the control group( P < 0. 05). During the treatment period,no significant adverse reactions occurred in the two groups. Conclusion Qili Qiangxin Capsules combined enalapril in the treatment of congestive heart failure can improve cardiac function and reduce the level of NT-pro BNP,and they have good safety.
作者
翟娜
徐健
张宇静
张岩
ZHAI Na;XU Jian;ZHANG Yujing;ZHANG Yan(Department of Cardiovascular Medicine,Shenyang First People's Hospital,Shenyang,Liaoning,China 110041)
出处
《中国药业》
CAS
2019年第16期64-66,共3页
China Pharmaceuticals
基金
辽宁省沈阳市科技计划项目[F-16-206-9-84]